NASDAQ:COYA Coya Therapeutics Q1 2026 Earnings Report $4.24 -0.02 (-0.49%) As of 03:51 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Coya Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.39Beat/MissN/AOne Year Ago EPSN/ACoya Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.15 millionBeat/MissN/AYoY Revenue GrowthN/ACoya Therapeutics Announcement DetailsQuarterQ1 2026Date5/12/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Coya Therapeutics Earnings HeadlinesCoya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in ...April 10, 2026 | finance.yahoo.comCoya Therapeutics Announces Leadership Changes and New DirectorApril 2, 2026 | tipranks.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 5 at 1:00 AM | Profits Run (Ad)Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy RatingMarch 23, 2026 | tipranks.comCoya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for ...March 18, 2026 | finance.yahoo.comPlus Therapeutics (PSTV) Gets a Buy from Lake StreetMarch 6, 2026 | theglobeandmail.comSee More Coya Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Coya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coya Therapeutics and other key companies, straight to your email. Email Address About Coya TherapeuticsCoya Therapeutics (NASDAQ:COYA) (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments. Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors. The company employs a proprietary screening platform to identify and optimize compounds that selectively bind or inhibit UNC-45A in diseased tissues, while minimizing off-target effects in healthy cells. In addition to its internal research, Coya has established collaborations with academic and industry partners to accelerate translational studies and position its candidates for clinical entry. Headquartered in Boston, Massachusetts, Coya Therapeutics leverages a multidisciplinary team of scientists with expertise in molecular biology, medicinal chemistry and translational medicine. The company is committed to advancing its pipeline through proof‐of‐concept studies, with the goal of delivering novel therapies that improve outcomes for patients suffering from high‐unmet‐need fibrotic and oncologic indications. Coya’s strategic focus on mechanistic innovation seeks to create durable treatment options where current standards of care are limited.View Coya Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings ARM (5/6/2026)AppLovin (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
